艾司氯胺酮对腰椎手术患者术后疼痛影响的研究

注册号:

Registration number:

ChiCTR2300071835 

最近更新日期:

Date of Last Refreshed on:

2023-08-20 23:53:43 

注册时间:

Date of Registration:

2023-05-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

艾司氯胺酮对腰椎手术患者术后疼痛影响的研究

Public title:

Effect of esketamine on postoperative pain in Patients Undergoing Lumbar Vertebral Surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司氯胺酮对腰椎手术患者术后疼痛影响的研究

Scientific title:

Effect of esketamine on postoperative pain in Patients Undergoing Lumbar Vertebral Surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪美如 

研究负责人:

孙斌 

Applicant:

Meiru Wang 

Study leader:

Bin Sun 

申请注册联系人电话:

Applicant telephone:

+86 150 0759 8140

研究负责人电话:

Study leader's
telephone:

+86 158 5215 2417

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangmeiru0925@163.com

研究负责人电子邮件:

Study leader's E-mail:

sun_bin66@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省徐州市泉山区解放南路199号

研究负责人通讯地址:

江苏省徐州市泉山区解放南路199号

Applicant address:

199 Jiefang Road South, Quanshan District, Xuzhou, Jiangsu,China

Study leader's address:

199 Jiefang Road South, Quanshan District, Xuzhou, Jiangsu,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省徐州市中心医院

Applicant's institution:

Xuzhou Central Hospital, Jiangsu Province

研究负责人所在单位:

江苏省徐州市中心医院

Affiliation of the Leader:

Xuzhou Central Hospital, Jiangsu Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XZXY-Lk-20230314-030

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

徐州市中心医院生物医学研究伦理审查委员会

Name of the ethic committee:

Biomedical Research Ethics Review Committee of Xuzhou Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-14 00:00:00

伦理委员会联系人:

张新新

Contact Name of the ethic committee:

Xinxin Zhang

伦理委员会联系地址:

中国江苏省徐州市泉山区解放南路199号

Contact Address of the ethic committee:

199 Jiefang Road South, Quanshan District, Xuzhou, Jiangsu,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 516 8395 6765

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省徐州市中心医院

Primary sponsor:

Xuzhou Central Hospital, Jiangsu

研究实施负责(组长)单位地址:

江苏省徐州市中心医院

Primary sponsor's address:

Xuzhou Central Hospital, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

徐州

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省徐州市中心医院

具体地址:

徐州解放南路199号

Institution
hospital:

Xuzhou Central Hospital, Jiangsu Province

Address:

No 199, Jiefang Road South, Xuzhou, Jiangsu

经费或物资来源:

研究生导师课题经费

Source(s) of funding:

Graduate student mentor project funds

研究疾病:

术后疼痛  

Target disease:

postoperative pain

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价艾司氯胺酮对腰椎融合术患者术后疼痛的影响。  

Objectives of Study:

To assess the effects of esketamine on postoperative pain in people undergoing lumbar fusion.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

艾司氯胺酮过敏史; 酗酒或镇痛药物依赖史; 合并严重高血压及严重心肝肺肾功能障碍疾病史; 严重感染性疾病、免疫系统疾病及血液系统疾病史; 认知功能障碍病史; 抑郁症、精神疾病病史; 患有严重感染性疾病、免疫系统疾病及血液系统疾病者

Exclusion criteria:

History of esketamine allergy; History of alcohol or analgesic drug dependence; History of severe hypertension and severe heart, liver, lung, and kidney dysfunction; History of serious infectious diseases, immune system disorders, and hematologic disorders; History of cognitive dysfunction; History of depression, psychiatric illness; 7. patients with serious infectious diseases, immune system diseases and blood system diseases

研究实施时间:

Study execute time:

From 2023-05-29 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-05-29 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

47

Group:

Control group

Sample size:

干预措施:

同体积生理盐水

干预措施代码:

Intervention:

Same volume of physiological saline

Intervention code:

组别:

低剂量艾司氯胺酮组

样本量:

47

Group:

Low-dose of esketamine group

Sample size:

干预措施:

低剂量艾司氯胺酮

干预措施代码:

Intervention:

Low-dose of esketamine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

徐州 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

徐州市中心医院 

单位级别:

三甲 

Institution
hospital:

Xuzhou central hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

首次按压镇痛泵时间

指标类型:

主要指标

Outcome:

Time of first pressure on the analgesia pump

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉药物使用量

指标类型:

次要指标

Outcome:

Amount of anesthetic drugs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后不良反应

指标类型:

次要指标

Outcome:

Postoperative adverse reaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛评分

指标类型:

次要指标

Outcome:

Postoperative pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机随机数表法,以1:1的比例将患者随机分配到两个组,两组分别接受低剂量艾司氯胺酮和生理盐水安慰剂。全部数据通过在线数据管理系统集中进行。

Randomization Procedure (please state who generates the random number sequence and by what method):

Using a computerized randomization scale, patients were randomly assigned in a 1:1 ratio to receive either low-dose esticketamine or placebo saline.All data are centralized through online data management system.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本试验要求研究中心工作人员在手术当日,麻醉马上开始之时获取和传达麻醉团队分组结果。治疗中的所有其他方面由临床团队决定,试验参与者和治疗临床医师不知晓分组结果。 主要结局数据由不知晓分组结果的试验数据收集人员通过术后随访的方式获得。

Blinding:

This trial asked site staff to obtain and communicate the results of the anesthesia team on the day of surgery, immediately after the start of anesthesia. All other aspects of treatment were decided by the clinical team, and trial participants and treating clinicians were not aware of the grouping results. Data for the primary outcomes were obtained by trial data collectors who did not know the results of the grouping through postoperative follow-up;

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不公开原始数据(请阅读网站首页注册指南共享原始数据的方式内容)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data is not exposed;

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究数据直接记录于实验记录本,并转换成电子数据保存于设有密码的计算机中,通过统计学软件绘制统计图表。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The study date will be recorded in our lab notebook and transformed into electric date in computers with the password. we will draw charts from statistics results by statistical software.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-05-26 09:40:00